Life Technologies to Accelerate Adoption of Next-Generation Sequencing in HLA …MarketWatch (press release)Accurate typing is needed to reduce the possibility of transplant rejection or the risk of graft versus host disease. HLAs are coded by a group …
XDx Launches AlloMap® Molecular Expression Testing in GermanySunHerald.comAlloMap is XDx's easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient's risk of acute cellular rejection wi…
Exclusive Video Q&A With Sijmen de Vries, CEO of PharmingMarketWatch (press release)… purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angioedema, Transplant Rej…
XDx Launches AlloMap® Molecular Expression Testing in GermanyMarketWatch (press release)AlloMap is XDx's easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient's risk of acute cellula…
Using transgenic technology for various applications in humans define Pharming …BioMedReports (subscription)… purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angi…
Orgenesis Inc. Announces Appointment of Senior LeadershipMarketWatch (press release)The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of …
Veloxis completes patient enrollment in LCP-Tacro 3002 pivotal Phase III trialPharmaceutical Business ReviewThe primary endpoint of the study is a composite endpoint, Biopsy Proven Acute Rejection, graft failure, loss to follow up or death and secondar…
A new work on a drug raising the prospect of a new life-prolonging drugHealth(Y) DestinationRapamycin is the drug that is used in widely in preventing transplant rejection and treat cancer. But the previous study of Rapamycin showed its positive effect…
Life-extending drug without the negative side effectsNew ScientistRapamycin is regularly given to prevent transplant rejection and treat cancer. Previous studies have also shown that it extends the life of animals, but simultaneously causes glucose int…
Veloxis Pharmaceuticals Completes Enrolment in LCP-Tacro™ 3002 Pivotal Phase …Sacramento BeeThe primary endpoint of the study, a composite endpoint (BPAR (Biopsy Proven Acute Rejection), graft failure, loss to follow up or death), will be evaluated…